![conference banner](/images/conference-banner.jpeg)
Abstract
The overexpression of anaplastic lymphoma kinase (ALK) had been found in many types of cancers, especially the non-small-cell lung cancers (NSCLCs). So the discovery of novel ALK inhibitor had attracted a great deal of interest in anticancer drugs research area. Presently, a combined study of 3D-quantitative structure-activity relationship (3DQSAR) and molecular docking was undertaken to explore the structural insights of 36 2-acyliminobenzimidazoles compounds influencing the ALK inhibitory activities. Both the ligand-based resultant comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) models exhibited good predictability (CoMFA with R2, 0.995; q2, 0.534; CoMSIA with R2, 0.993; q2, 0.519;). 3D contour maps and docking results suggested different groups on the core parts of the componds could enhance the biological activities. Finally, 10 derivatives as potential candidates of ALK inhibitors with excellent predicted activities were designed.
Keywords: 3D-QSAR, ALK inhibitor, CoMFA, CoMSIA, docking.
Letters in Drug Design & Discovery
Title:3D-QSAR and Docking Studies on 2-acyliminobenzimidazoles Derivatives as Potent ALK Inhibitors
Volume: 12 Issue: 3
Author(s): Qianqian Lva, Zhi Wang, Zhonghua Wanga*, Fanhong Wu*Liping Cheng
Affiliation:
- School of Chemical and Environmental Engineering, Shanghai Institute of Technology, Shanghai,China
- School of Chemical and Environmental Engineering, Shanghai Institute of Technology, Shanghai,China
Keywords: 3D-QSAR, ALK inhibitor, CoMFA, CoMSIA, docking.
Abstract: The overexpression of anaplastic lymphoma kinase (ALK) had been found in many types of cancers, especially the non-small-cell lung cancers (NSCLCs). So the discovery of novel ALK inhibitor had attracted a great deal of interest in anticancer drugs research area. Presently, a combined study of 3D-quantitative structure-activity relationship (3DQSAR) and molecular docking was undertaken to explore the structural insights of 36 2-acyliminobenzimidazoles compounds influencing the ALK inhibitory activities. Both the ligand-based resultant comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) models exhibited good predictability (CoMFA with R2, 0.995; q2, 0.534; CoMSIA with R2, 0.993; q2, 0.519;). 3D contour maps and docking results suggested different groups on the core parts of the componds could enhance the biological activities. Finally, 10 derivatives as potential candidates of ALK inhibitors with excellent predicted activities were designed.
Export Options
About this article
Cite this article as:
Lva Qianqian, Wang Zhi, Wanga Zhonghua*, Wu Fanhong*, Cheng Liping, 3D-QSAR and Docking Studies on 2-acyliminobenzimidazoles Derivatives as Potent ALK Inhibitors, Letters in Drug Design & Discovery 2015; 12 (3) . https://dx.doi.org/10.2174/1570180811666141010001624
DOI https://dx.doi.org/10.2174/1570180811666141010001624 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
Call for Papers in Thematic Issues
Navigating the Frontier: Probiotics' Promising Path in Combatting Viral Respiratory Infections, Spotlight on Coronaviridae.
Probiotics, well-known for their role in gut health, show promise in preventing and managing respiratory virus infections, particularly in children and at-risk populations. However, the profound influence of novel pathogenic viral RTIs such as coronaviruses has reshaped perspectives on the potential of probiotics. Despite their potential, significant gaps remain in ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways
Current Cancer Drug Targets MicroRNA-203: Tumor Suppression and Beyond
MicroRNA A Review of Recent Patents on the Protozoan Parasite HSP90 as a Drug Target
Recent Patents on Biotechnology Diaryl Urea: A Privileged Structure in Anticancer Agents
Current Medicinal Chemistry 99mTc-(tricine)-HYNIC-Lys-FROP Peptide for Breast Tumor Targeting
Anti-Cancer Agents in Medicinal Chemistry A Content-based Image Retrieval Scheme for Lung Nodule Classification
Current Medical Imaging Piperine as a Potential Anti-cancer Agent: A Review on Preclinical Studies
Current Medicinal Chemistry Understanding Molecular Pathways and Targets of Brachyury in Epithelial-mesenchymal Transition (EMT) in Human Cancers
Current Cancer Drug Targets Stem Cell Defects in Philadelphia Chromosome Negative Chronic Myeloproliferative Disorders: A Phenotypic and Molecular Puzzle?
Current Stem Cell Research & Therapy Cellular Uptake of Neutral Phosphorodiamidate Morpholino Oligomers
Current Pharmaceutical Biotechnology Dietary Fish Oil Reduces Colon Cancer Risk
Current Organic Chemistry Mitochondrial Physiology and Toxicity (Mitotoxicity); Importance for the Immune System, Programmed Cell Death and Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress
Current Pharmaceutical Biotechnology Contribution of Stemness-Linked Transcription Regulators to the Progression of Breast Cancer
Current Molecular Medicine Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Angiogenesis and Angiogenic Inhibitors in Non Small Cell Lung Cancer
Current Angiogenesis (Discontinued) On The Edge of Validation – Cancer Protease Fibroblast Activation Protein
Mini-Reviews in Medicinal Chemistry AMPA Receptor Antagonist CFM-2 Decreases Survivin Expression in Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Using Nutrigenomics to Evaluate Apoptosis as a Preemptive Target in Cancer Prevention
Current Cancer Drug Targets Exploring Confluence-Related Signalling to Modulate the Expression of Oct4 – A Role in Facilitating Mouse Somatic Cell Reprogramming?
Current Stem Cell Research & Therapy